Adverse and beneficial effects of tocolytic therapy.

Abstract

In addition to questions raised about the efficacy of many tocolytics, appropriate concern has been voiced about the safety of these potent drugs. Although some degree of risk for adverse effects with drugs promising a strong therapeutic effect can be accepted, caution needs to be exercised when benefits are marginal or unproven. Unfortunately, some of the tocolytics, most notably the betamimetics and magnesium sulfate, have been found to have considerable potential for adverse maternal cardiovascular and respiratory effects. Although less clearly established, the use of indomethacin appears to be associated with increased fetal and neonatal risks. Concerning magnesium sulfate, in addition to the well-known maternal effects, the accumulating evidence showing an increased frequency of adverse outcomes in the fetus and neonate has led to the recommendations to abandon its use entirely as a tocolytic. Given the limitations of our current state of knowledge, nifedipine would appear to be among the more efficacious and safer tocolytics available to use when properly indicated.

02040'04'05'06'07'08'09'10'11'12'13'14'15'16'17
Citations per Year

98 Citations

Semantic Scholar estimates that this publication has 98 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Pryde2001AdverseAB, title={Adverse and beneficial effects of tocolytic therapy.}, author={Peter G Pryde and Richard E Besinger and John G Gianopoulos and Robert Mittendorf}, journal={Seminars in perinatology}, year={2001}, volume={25 5}, pages={316-40} }